Life Science Institute,Inc.
Mitsubishi Chemical Holdings Group

Regenerative Medicine

Announcement

Life Sciences Institute, Inc. has merged with Clio, Inc., a wholly owned subsidiary, as of January 1, 2017, and Clio, Inc. was dissolved.
Research and development projects from the former Clio, Inc., such as regenerative medicine products using Muse cells, have been taken on by Life Science Institute, Inc.

What are Muse cells?

“Muse cells” – Toward Regenerative Medicine –

Muse cells were discovered by a team led by Professor Mari Dezawa of Tohoku University in 2010. They exist in the human body, such as in bone marrow and skin (dermis). These stem cells can differentiate into a variety of cells that build different parts of the body. When injected into human body, Muse cells migrate to a damaged organ to perform tissue repair. Muse cell preparations offer the following advantages: intravenous infusion decreases the physical burden on the patient, Muse cells are less likely to form tumors, and a single preparation can be applied to multiple diseases.
Life Science Institute, Inc. started a clinical study using Muse cells for patients with acute myocardial infarction in January 2018. After confirming the efficacy and safety, Life Science Institute, Inc. plans to develop the technology for a variety of diseases.

Schematic diagram of when Muse cells are applied to acute myocardial infarction

Schematic

Mitsubishi Chemical Holdings Group

Mitsubishi Chemical Holdings Corporation
MITSUBISHI CHEMICAL CORPORATION
Mitsubishi Tanabe Pharma
MITSUBISHI PLASTICS, INC.
MITSUBISHI RAYON CO., LTD
Life Science Institute,Inc.
TAIYO NIPPON SANSO
Page Top